Disclosed is the use of an immunomodulator comprising a non-pathogenic heat-killed whole cell Mycobacterium in the preparation of a medicament for use in the treatment and/or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously, separately or sequentially with administration of the immunomodulator, wherein the Mycobacterium is M. obuense wherein said immunogenic cell death therapy is selected from microwave irradiation, targeted radiotherapy, embolisation, cryotherapy, ultrasound, high intensity focused ultrasound, cyberknife, hyperthermia, radiofrequency ablation, cryoablation, electrotome heating, hot water injection, alcohol injection, embolization, radiation exposure, photodynamic therapy, laser beam irradiation, and combinations thereof wherein said immunogenic cell death therapy is to be carried out at a sub-optimal level that is not intended to fully remove or eradicate the tumour of said neoplastic disease.
